IL318163A - Bicyclic tetrahydrothiazepine derivatives - Google Patents

Bicyclic tetrahydrothiazepine derivatives

Info

Publication number
IL318163A
IL318163A IL318163A IL31816325A IL318163A IL 318163 A IL318163 A IL 318163A IL 318163 A IL318163 A IL 318163A IL 31816325 A IL31816325 A IL 31816325A IL 318163 A IL318163 A IL 318163A
Authority
IL
Israel
Prior art keywords
tetrahydrothiazepine
bicyclic
derivatives
tetrahydrothiazepine derivatives
bicyclic tetrahydrothiazepine
Prior art date
Application number
IL318163A
Other languages
Hebrew (he)
Inventor
Marco Brandstaetter
Francesco Maria Emilia Di
Roman Hutter
Holger Kuehne
Thomas Luebbers
Laetitia Janine Martin
Barbara Johanna Mueller
Original Assignee
Hoffmann La Roche
Marco Brandstaetter
Francesco Maria Emilia Di
Roman Hutter
Holger Kuehne
Thomas Luebbers
Laetitia Janine Martin
Barbara Johanna Mueller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Marco Brandstaetter, Francesco Maria Emilia Di, Roman Hutter, Holger Kuehne, Thomas Luebbers, Laetitia Janine Martin, Barbara Johanna Mueller filed Critical Hoffmann La Roche
Publication of IL318163A publication Critical patent/IL318163A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL318163A 2022-08-11 2023-08-09 Bicyclic tetrahydrothiazepine derivatives IL318163A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22189817 2022-08-11
PCT/EP2023/071988 WO2024033388A1 (en) 2022-08-11 2023-08-09 Bicyclic tetrahydrothiazepine derivatives

Publications (1)

Publication Number Publication Date
IL318163A true IL318163A (en) 2025-03-01

Family

ID=82898783

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318163A IL318163A (en) 2022-08-11 2023-08-09 Bicyclic tetrahydrothiazepine derivatives

Country Status (17)

Country Link
US (1) US20260035364A1 (en)
EP (1) EP4568958A1 (en)
JP (1) JP2025526727A (en)
KR (1) KR20250038674A (en)
CN (1) CN119698413A (en)
AR (1) AR130194A1 (en)
AU (1) AU2023322637A1 (en)
CL (1) CL2025000379A1 (en)
CO (1) CO2025001103A2 (en)
CR (1) CR20250042A (en)
IL (1) IL318163A (en)
MA (1) MA71727A (en)
MX (1) MX2025000918A (en)
PE (1) PE20251399A1 (en)
TW (1) TW202417438A (en)
WO (1) WO2024033388A1 (en)
ZA (1) ZA202408363B (en)

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
DE69025946T2 (en) 1989-09-08 1996-10-17 Univ Duke MODIFICATIONS OF THE STRUCTURE OF THE EGF RECEPTOR GENE IN HUMAN GLIOMA
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE207366T1 (en) 1993-12-24 2001-11-15 Merck Patent Gmbh IMMUNOCONJUGATES
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
KR100441557B1 (en) 1994-07-21 2005-08-05 아크조 노벨 엔.브이. Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
ATE446955T1 (en) 1995-03-30 2009-11-15 Pfizer Prod Inc QUINAZOLINONE DERIVATIVES
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
PL188959B1 (en) 1995-07-06 2005-05-31 Novartis Ag Pyrollepyrimidines and methods of obtaining them
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (en) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 Irreversible inhibitors of tyrosine kinases
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (en) 1996-10-02 1998-04-16 Novartis Ag PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT
UA73073C2 (en) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
CN1160338C (en) 1998-11-19 2004-08-04 沃尼尔·朗伯公司 N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, irreversible Tyrosine Kinase Inhibitors
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP5238936B2 (en) 2005-03-25 2013-07-17 ジーアイティーアール,インク. GITR binding molecules and uses thereof
DK1879573T3 (en) 2005-05-10 2013-02-25 Incyte Corp MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE AND METHODS FOR USING IT
KR101704734B1 (en) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. Human monoclonal antibodies to programmed death ligand 1(pd-l1)
ES2540561T3 (en) 2005-12-20 2015-07-10 Incyte Corporation N-hydroxyamidinoheterocycles as indolamine 2,3-dioxygenase modulators
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (en) 2006-09-19 2008-02-08 Incyte Corp COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (en) 2007-07-12 2016-09-21 Gitr Inc Combination therapies employing gitr binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
AU2008353145B2 (en) 2008-01-03 2013-09-12 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
MX356367B (en) 2008-12-09 2018-05-25 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function.
IN2015DN02826A (en) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
DK2542256T3 (en) 2010-03-04 2019-08-26 Macrogenics Inc ANTIBODIES REACTIVE WITH B7-H3, IMMUNOLOGICALLY ACTIVE FRAGMENTS THEREOF AND APPLICATIONS THEREOF
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
NO2694640T3 (en) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (en) 2011-11-28 2022-08-16 Merck Patent Gmbh ANTI-PD-L1 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND COMPOSITION
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
RU2015105561A (en) * 2012-08-09 2016-09-27 Ф. Хоффманн-Ля Рош Аг SUBSTITUTED HETEROAZEPINONES
JP6727224B2 (en) 2015-03-02 2020-07-22 アペイロン・バイオロジックス・アクチェンゲゼルシャフトAPEIRON Biologics AG Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases
MX2023009379A (en) * 2021-02-12 2023-10-10 Hoffmann La Roche Bicyclic tetrahydroazepine derivatives for the treatment of cancer.

Also Published As

Publication number Publication date
EP4568958A1 (en) 2025-06-18
PE20251399A1 (en) 2025-05-22
CR20250042A (en) 2025-03-25
MX2025000918A (en) 2025-03-07
JP2025526727A (en) 2025-08-15
TW202417438A (en) 2024-05-01
WO2024033388A1 (en) 2024-02-15
AU2023322637A1 (en) 2024-11-14
ZA202408363B (en) 2025-10-29
CO2025001103A2 (en) 2025-02-13
AR130194A1 (en) 2024-11-13
KR20250038674A (en) 2025-03-19
US20260035364A1 (en) 2026-02-05
CN119698413A (en) 2025-03-25
CL2025000379A1 (en) 2025-04-11
MA71727A (en) 2025-05-30

Similar Documents

Publication Publication Date Title
PL4396183T3 (en) Substituted s-alaninate derivatives
CA208008S (en) Washbasin
ZA202408363B (en) Bicyclic tetrahydrothiazepine derivatives
IL316935A (en) Bicyclic tetrahydrothiazepine derivatives
IL304189A (en) Pyrazoleamide derivatives
HK40127193A (en) Bicyclic tetrahydrothiazepine derivatives
CA3262134A1 (en) Bicyclic tetrahydrothiazepine derivatives
HK40120678A (en) Bicyclic tetrahydrothiazepine derivatives
HK40121027A (en) Bicyclic tetrahydrothiazepine derivatives
GB2607640B (en) Urinal
CA208004S (en) Washbasin
HK40127201A (en) Bicyclic tetrahydroazepine derivatives
CA214156S (en) Urinal
GB202304824D0 (en) Bicyclic compounds
HK40101062A (en) Bicyclic compounds
HK40100114A (en) Bicyclic compounds
EM87765530001S (en) Stair rails
EM87765530003S (en) Stair rails
CA208000S (en) Washbasin
EM87765530002S (en) Stair rails (part of -)
GB202210401D0 (en) Connevtor fitting
EM87693350003S (en) Towel rails
EM87693350001S (en) Towel rails
EM87693350002S (en) Towel rails
EM87628270001S (en) Towel rails